Novo Nordisk and IBM Watson are partnering to create an AI system to help diabetes patients better manage their disease.
Data from continuous blood sugar monitors will be analyzed and used to inform treatment decisions, such as insulin dosage. Food intake, exercise and the timing and dosage of insulin injections could also be added to the equation.
The company believes that incorporating large amounts of data into self-care decisions can enable better choices.
Wearable Tech + Digital Health San Francisco – April 5, 2016 @ the Mission Bay Conference Center
NeuroTech San Francisco – April 6, 2016 @ the Mission Bay Conference Center
Wearable Tech + Digital Health NYC – June 7, 2016 @ the New York Academy of Sciences
NeuroTech NYC – June 8, 2016 @ the New York Academy of Sciences